Mechanism-independent optimization of combinatorial nanodiamond and unmodified drug delivery using a phenotypically driven platform technology

ACS Nano

Volumn 9, Issue 3, 2015, Pages 3332-3344

  Wang, Hann ^a,b,c,d   Lee, Dong Keun ^a,b,c,d   Chen, Kai Yu ^a,b,c,d   Chen, Jing Yao ^d   Zhang, Kangyi ^a,b,c   Silva, Aleidy ^a   Ho, Chih Ming ^a   Ho, Dean ^a,b,c,d  

^a Engineering IV   (United States)

^b UCLA SCHOOL OF DENTISTRY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biocompatibility; breast cancer; drug delivery; nanodiamond; nanomedicine; optimization

Indexed keywords

BIOCOMPATIBILITY; CELL CULTURE; CHEMOTHERAPY; DISEASES; DRUG DELIVERY; MEDICAL NANOTECHNOLOGY; NANODIAMONDS; OPTIMIZATION; POPULATION STATISTICS; TARGETED DRUG DELIVERY;

BREAST CANCER; COMBINATION CHEMOTHERAPY; COMBINATION OPTIMIZATION; COMBINATION TREATMENTS; DRUG ADMINISTRATION; OPTIMAL COMBINATION; POPULATION HETEROGENEITY; THERAPEUTIC EFFICACY;

CONTROLLED DRUG DELIVERY;

ANTINEOPLASTIC AGENT; DRUG CARRIER; NANODIAMOND;

ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; HUMAN; NANOMEDICINE; PHENOTYPE; PROCEDURES; RAT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; HUMANS; NANODIAMONDS; NANOMEDICINE; PHENOTYPE; RATS;

EID: 84925639530     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/acsnano.5b00638     Document Type: Article

References (83)

1. Zhao, B.; Pritchard, J. R.; Lauffenburger, D. A.; Hemann, M. T. Addressing Genetic Tumor Heterogeneity through Computationally Predictive Combination Therapy Cancer Discovery 2014, 4, 166-174
2. Al-Lazikani, B.; Banerji, U.; Workman, P. Combinatorial Drug Therapy for Cancer in the Post-genomic Era Nat. Biotechnol. 2012, 30, 679-692
3. Kummar, S.; Chen, H. X.; Wright, J.; Holbeck, S.; Millin, M. D.; Tomaszewski, J.; Zweibel, J.; Collins, J.; Doroshow, J. H. Utilizing Targeted Cancer Therapeutic Agents in Combination: Novel Approaches and Urgent Requirements Nat. Rev. Drug Discovery 2010, 9, 843-856
4. Munos, B. Lessons from 60 Years of Pharmaceutical Innovation Nat. Rev. Drug Discovery 2009, 8, 959-968
5. Fitzgerald, J. B.; Schoeberl, B.; Nielsen, U. B.; Sorger, P. K. Systems Biology and Combination Therapy in the Quest for Clinical Efficacy Nat. Chem. Biol. 2006, 2, 458-466
6. Kreeger, P. K.; Lauffenburger, D. A. Cancer Systems Biology: A Network Modeling Perspective Carcinogenesis 2010, 31, 2-8
7. Barabasi, A.-L.; Oltvai, Z. N. Network Biology: Understanding the Cells Functional Organization Nat. Rev. Genet. 2004, 5, 101-113
8. Watts, D. J.; Strogatz, S. H. Collective Dynamics of Small-World Networks Nature 1998, 393, 440-442
9. Jeong, H.; Tombor, B.; Albert, R.; Oltvai, Z. N.; Barabási, A.-L. The Large Scale Organization of Metabolic Networks Nature 2000, 407, 651-654
10. Hood, L.; Heath, J. R.; Phelps, M. E.; Lin, B. Systems Biology and New Technologies Enable Predictive and Preventative Medicine Science 2004, 306, 640-643
11. Persidis, A. Cancer Multidrug Resistance Nat. Biotechnol. 1999, 17, 94-95
12. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug Resistance in Cancer: Role of ATP-Dependent Transporters Nat. Rev. Cancer 2002, 2, 48-58
13. Doyle, L. A.; Yang, W.; Abruzzo, L. V.; Krogmann, T.; Gao, Y.; Rishi, A. K.; Ross, D. D. A Multidrug Resistance Transporter from Human MCF-7 Breast Cancer Cells Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15665-15670
14. Goldstein, L. J.; Galski, H.; Fojo, A.; Willingham, M.; Lai, S.-L.; Gazdar, A.; Pirker, R.; Green, A.; Crist, W.; Brodeur, G. M. Expression of Multidrug Resistance Gene in Human Cancers J. Natl. Cancer Inst. 1989, 81, 116-124
15. Lage, H. An Overview of Cancer Multidrug Resistance: A Still Unsolved Problem Cell. Mol. Life Sci. 2008, 65, 3145-3167
16. Cole, S. P.; Bhardwaj, G.; Gerlach, J. H.; Mackie, J. E.; Grant, C. E.; Almquist, K. C.; Stewart, A. J.; Kurz, E. U.; Duncan, A. M.; Deeley, R. G. Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line Science 1992, 258, 1650-1654
17. ágoston, V.; Csermely, P.; Pongor, S. Multiple Weak Hits Confuse Complex Systems: A Transcriptional Regulatory Network as an Example Phys. Rev. E 2005, 71, 051909
18. Bozic, I.; Reiter, J. G.; Allen, B.; Antal, T.; Chatterjee, K.; Shah, P.; Moon, Y. S.; Yaqubie, A.; Kelly, N.; Le, D. T. Evolutionary Dynamics of Cancer in Response to Targeted Combination Therapy eLife 2013, 2, e00747
19. Holmes, F. A.; Walters, R. S.; Theriault, R. L.; Buzdar, A. U.; Frye, D. K.; Hortobagyi, G. N.; Forman, A. D.; Newton, L. K.; Raber, M. N. Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer J. Natl. Cancer Inst. 1991, 83, 1797-1805
20. Hellman, S.; Rosenberg, S. A.; DeVita, V. T. Cancer: Principles & Practice of Oncology; Lippincott-Raven: Philadelphia, PA, 1997; Vol. 2.
21. Ciardiello, F.; Caputo, R.; Bianco, R.; Damiano, V.; Pomatico, G.; De Placido, S.; Bianco, A. R.; Tortora, G. Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa), an Epidermal Growth Factor Receptor-Selective Tyrosine Kinase Inhibitor Clin. Cancer Res. 2000, 6, 2053-2063
22. de Gramont, A. D.; Figer, A.; Seymour, M.; Homerin, M.; Hmissi, A.; Cassidy, J.; Boni, C.; Cortes-Funes, H.; Cervantes, A.; Freyer, G. Leucovorin and Fluorouracil with or without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer J. Clin. Oncol. 2000, 18, 2938-2947
23. OShaughnessy, J.; Miles, D.; Vukelja, S.; Moiseyenko, V.; Ayoub, J.-P.; Cervantes, G.; Fumoleau, P.; Jones, S.; Lui, W.-Y.; Mauriac, L. Superior Survival with Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients with Advanced Breast Cancer: Phase III Trial Results J. Clin. Oncol. 2002, 20, 2812-2823
24. Goldberg, R. M.; Sargent, D. J.; Morton, R. F.; Fuchs, C. S.; Ramanathan, R. K.; Williamson, S. K.; Findlay, B. P.; Pitot, H. C.; Alberts, S. R. A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients with Previously Untreated Metastatic Colorectal Cancer J. Clin. Oncol. 2004, 22, 23-30
25. Peppas, N. A.; Hilt, J. Z.; Khademhosseini, A.; Langer, R. Hydrogels in Biology and Medicine: From Molecular Principles to Bionanotechnology Adv. Mater. 2006, 18, 1345-1360
26. Colombo, M.; Carregal-Romero, S.; Casula, M. F.; Gutiérrez, L.; Morales, M. P.; Böhm, I. B.; Heverhagen, J. T.; Prosperi, D.; Parak, W. J. Biological Applications of Magnetic Nanoparticles Chem. Soc. Rev. 2012, 41, 4306-4334
27. Montenegro, J.-M.; Grazu, V.; Sukhanova, A.; Agarwal, S.; de la Fuente, J. M.; Nabiev, I.; Greiner, A.; Parak, W. J. Controlled Antibody/(Bio-) Conjugation of Inorganic Nanoparticles for Targeted Delivery Adv. Drug Delivery Rev. 2013, 65, 677-688
28. Farokhzad, O. C.; Jon, S.; Khademhosseini, A.; Tran, T.-N. T.; LaVan, D. A.; Langer, R. Nanoparticle-Aptamer Bioconjugates a New Approach for Targeting Prostate Cancer Cells Cancer Res. 2004, 64, 7668-7672
29. Xu, X.; Xie, K.; Zhang, X.-Q.; Pridgen, E. M.; Park, G. Y.; Cui, D. S.; Shi, J.; Wu, J.; Kantoff, P. W.; Lippard, S. J. Enhancing Tumor Cell Response to Chemotherapy through Nanoparticle-Mediated Codelivery of siRNA and Cisplatin Prodrug Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 18638-18643
30. Zhang, X.-Q.; Xu, X.; Lam, R.; Giljohann, D.; Ho, D.; Mirkin, C. A. Strategy for Increasing Drug Solubility and Efficacy through Covalent Attachment to Polyvalent DNA-Nanoparticle Conjugates ACS Nano 2011, 5, 6962-6970
31. Dhar, S.; Daniel, W. L.; Giljohann, D. A.; Mirkin, C. A.; Lippard, S. J. Polyvalent Oligonucleotide Gold Nanoparticle Conjugates as Delivery Vehicles for Platinum (IV) Warheads J. Am. Chem. Soc. 2009, 131, 14652-14653
32. Gharpure, K. M.; Chu, K. S.; Bowerman, C.; Miyake, T.; Pradeep, S.; Mangala, L. S.; Han, H.-D.; Rupaimoole, R.; Armaiz-Pena, G. N.; Rahhal, T. B. Metronomic Docetaxel in PRINT® Nanoparticles and EZH2 Silencing Have Synergistic Antitumor Effect in Ovarian Cancer Mol. Cancer Ther. 2014, 13, 1750-1757
33. Von Maltzahn, G.; Park, J.-H.; Lin, K. Y.; Singh, N.; Schwöppe, C.; Mesters, R.; Berdel, W. E.; Ruoslahti, E.; Sailor, M. J.; Bhatia, S. N. Nanoparticles That Communicate in Vivo To Amplify Tumour Targeting Nat. Mater. 2011, 10, 545-552
34. Uskokovic, V.; Lee, K.; Lee, P. P.; Fischer, K. E.; Desai, T. A. Shape Effect in the Design of Nanowire-Coated Microparticles as Transepithelial Drug Delivery Devices ACS Nano 2012, 6, 7832-7841
35. Chirra, H. D.; Desai, T. A. Multi-reservoir Bioadhesive Microdevices for Independent Rate-Controlled Delivery of Multiple Drugs Small 2012, 8, 3839-3846
36. Davis, M. E.; Zuckerman, J. E.; Choi, C. H. J.; Seligson, D.; Tolcher, A.; Alabi, C. A.; Yen, Y.; Heidel, J. D.; Ribas, A. Evidence of RNAi in Humans from Systemically Administered siRNA via Targeted Nanoparticles Nature 2010, 464, 1067-1070
37. Creixell, M.; Peppas, N. A. Co-delivery of siRNA and Therapeutic Agents Using Nanocarriers To Overcome Cancer Resistance Nano Today 2012, 7, 367-379
38. Perrault, S. D.; Chan, W. C. In Vivo Assembly of Nanoparticle Components To Improve Targeted Cancer Imaging Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 11194-11199
39. Eltoukhy, A. A.; Chen, D.; Alabi, C. A.; Langer, R.; Anderson, D. G. Degradable Terpolymers with Alkyl Side Chains Demonstrate Enhanced Gene Delivery Potency and Nanoparticle Stability Adv. Mater. 2013, 25, 1487-1493
40. Gobin, A. M.; Lee, M. H.; Halas, N. J.; James, W. D.; Drezek, R. A.; West, J. L. Near-Infrared Resonant Nanoshells for Combined Optical Imaging and Photothermal Cancer Therapy Nano Lett. 2007, 7, 1929-1934
41. Chow, E. K.; Zhang, X.-Q.; Chen, M.; Lam, R.; Robinson, E.; Huang, H.; Schaffer, D.; Osawa, E.; Goga, A.; Ho, D. Nanodiamond Therapeutic Delivery Agents Mediate Enhanced Chemoresistant Tumor Treatment Sci. Transl. Med. 2011, 3, 73ra21
42. Chow, E. K.-H.; Ho, D. Cancer Nanomedicine: From Drug Delivery to Imaging Sci. Transl. Med. 2013, 5, 216rv4
43. Moore, L.; Chow, E. K. H.; Osawa, E.; Bishop, J. M.; Ho, D. Diamond-Lipid Hybrids Enhance Chemotherapeutic Tolerance and Mediate Tumor Regression Adv. Mater. 2013, 25, 3532-3541
44. Chen, M.; Pierstorff, E. D.; Lam, R.; Li, S.-Y.; Huang, H.; Osawa, E.; Ho, D. Nanodiamond-Mediated Delivery of Water-Insoluble Therapeutics ACS Nano 2009, 3, 2016-2022
45. Toh, T. B.; Lee, D.-K.; Hou, W.; Abdullah, L. N.; Nguyen, J.; Ho, D.; Chow, E. Nanodiamond-Mitoxantrone Complexes Enhance Drug Retention in Chemoresistant Breast Cancer Cells Mol. Pharmaceutics 2014, 11, 2683-2691
46. Loewe, S. The Problem of Synergism and Antagonism of Combined Drugs Arzneimittelforschung 1953, 3, 285-290
47. Chou, T.-C.; Talalay, P. Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors Adv. Enzyme Regul. 1984, 22, 27-55
48. Bliss, C. The Calculation of Microbial Assays Bacteriol. Rev. 1956, 20, 243-258
49. Wong, P. K.; Yu, F.; Shahangian, A.; Cheng, G.; Sun, R.; Ho, C.-M. Closed-Loop Control of Cellular Functions Using Combinatory Drugs Guided by a Stochastic Search Algorithm Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 5105-5110
50. Valamehr, B.; Tsutsui, H.; Ho, C.-M.; Wu, H. Developing Defined Culture Systems for Human Pluripotent Stem Cells Regener. Med. 2011, 6, 623-634
51. Al-Shyoukh, I.; Yu, F.; Feng, J.; Yan, K.; Dubinett, S.; Ho, C.-M.; Shamma, J. S.; Sun, R. Systematic Quantitative Characterization of Cellular Responses Induced by Multiple Signals BMC Syst. Biol. 2011, 5, 88
52. Yu, F.; Al-Shyoukh, I.; Feng, J.; Li, X.; Liao, C. W.; Ho, C.-M.; Shamma, J. S.; Sun, R. Control of Kaposis Sarcoma-Associated Herpesvirus Reactivation Induced by Multiple Signals PLoS One 2011, 6, e20998
53. Wei, F.; Bai, B.; Ho, C.-M. Rapidly Optimizing an Aptamer Based BoNT Sensor by Feedback System Control (FSC) Scheme Biosens. Bioelectron. 2011, 30, 174-179
54. Yu, H.; Zhang, W. L.; Ding, X.; Zheng, K. Y.; Ho, C.-M.; Tsim, K. W.; Lee, Y.-K. Optimizing Combinations of Flavonoids Deriving from Astragali Radix in Activating the Regulatory Element of Erythropoietin by a Feedback System Control Scheme J. Evidence-Based Complementary Altern. Med. 2013, 541436
55. Ding, X.; Sanchez, D. J.; Shahangian, A.; Al-Shyoukh, I.; Cheng, G.; Ho, C.-M. Cascade Search for HSV-1 Combinatorial Drugs with High Antiviral Efficacy and Low Toxicity Int. J. Nanomed. 2012, 7, 2281-2292
56. Wang, H.; Silva, A.; Ho, C.-M. When Medicine Meets Engineering-Paradigm Shifts in Diagnostics and Therapeutics Diagnostics 2013, 3, 126-154
57. Honda, Y.; Ding, X.; Mussano, F.; Wiberg, A.; Ho, C.-m.; Nishimura, I. Guiding the Osteogenic Fate of Mouse and Human Mesenchymal Stem Cells through Feedback System Control Sci. Rep. 2013, 3, 3420
58. Tsutsui, H.; Valamehr, B.; Hindoyan, A.; Qiao, R.; Ding, X.; Guo, S.; Witte, O. N.; Liu, X.; Ho, C.-M.; Wu, H. An Optimized Small Molecule Inhibitor Cocktail Supports Long-Term Maintenance of Human Embryonic Stem Cells Nat. Commun. 2011, 2, 167
59. Ding, X.; Xu, H.; Hopper, C.; Yang, J.; Ho, C. M. Use of Fractional Factorial Designs in Antiviral Drug Studies Qual. Reliab. Eng. Int. 2013, 29, 299-304
60. McKay, M. D.; Beckman, R. J.; Conover, W. J. Comparison of Three Methods for Selecting Values of Input Variables in the Analysis of Output from a Computer Code Technometrics 1979, 21, 239-245
61. Storn, R.; Price, K. Differential Evolution-A Simple and Efficient Heuristic for Global Optimization over Continuous Spaces J. Global Optim. 1997, 11, 341-359
62. Liang, Y.; Ozawa, M.; Krueger, A. A General Procedure To Functionalize Agglomerating Nanoparticles Demonstrated on Nanodiamond ACS Nano 2009, 3, 2288-2296
63. Barnard, A. S. Diamond Standard in Diagnostics: Nanodiamond Biolabels Make Their Mark Analyst 2009, 134, 1751-1764
64. Barnard, A. S. Self-Assembly in Nanodiamond Agglutinates J. Mater. Chem. 2008, 18, 4038-4041
65. McGuinness, L. P.; Yan, Y.; Stacey, A.; Simpson, D. A.; Hall, L. T.; Maclaurin, D.; Prawer, S.; Mulvaney, P.; Wrachtrup, J.; Caruso, F. Quantum Measurement and Orientation Tracking of Fluorescent Nanodiamonds Inside Living Cells Nat. Nanotechnol. 2011, 6, 358-363
66. Mohan, N.; Chen, C.-S.; Hsieh, H.-H.; Wu, Y.-C.; Chang, H.-C. In Vivo Imaging and Toxicity Assessments of Fluorescent Nanodiamonds in Caenorhabditis elegans Nano Lett. 2010, 10, 3692-3699
67. Mochalin, V. N.; Gogotsi, Y. Wet Chemistry Route to Hydrophobic Blue Fluorescent Nanodiamond J. Am. Chem. Soc. 2009, 131, 4594-4595
68. Chang, L.-Y.; Osawa, E.; Barnard, A. S. Confirmation of the Electrostatic Self-Assembly of Nanodiamonds Nanoscale 2011, 3, 958-962
69. Barnard, A. S.; Sternberg, M. Crystallinity and Surface Electrostatics of Diamond Nanocrystals J. Mater. Chem. 2007, 17, 4811-4819
70. Barnard, A. S.; Osawa, E. The Impact of Structural Polydispersivity on the Surface Electrostatic Potential of Nanodiamond Nanoscale 2014, 6, 1188-1194
71. Cohen, J. Statistical Power Analysis for the Behavioral Sciences; Taylor and Francis: New York, 1988.
72. Xi, G.; Robinson, E.; Mania-Farnell, B.; Vanin, E. F.; Shim, K.-W.; Takao, T.; Allender, E. V.; Mayanil, C. S.; Soares, M. B.; Ho, D. Convection-Enhanced Delivery of Nanodiamond Drug Delivery Platforms for Intracranial Tumor Treatment Nanomedicine 2014, 10, 381-391
73. Wood, K.; Nishida, S.; Sontag, E. D.; Cluzel, P. Mechanism-Independent Method for Predicting Response to Multidrug Combinations in Bacteria Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 12254-12259
74. Giordano, S.; Petrelli, A. From Single- to Multi-target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage Curr. Med. Chem. 2008, 15, 422-432
75. Gottesman, M. M. Mechanisms of Cancer Drug Resistance Annu. Rev. Med. 2002, 53, 615-627
76. Jänne, P. A.; Gray, N.; Settleman, J. Factors Underlying Sensitivity of Cancers to Small-Molecule Kinase Inhibitors Nat. Rev. Drug Discovery 2009, 8, 709-723
77. Komarova, N. L.; Wodarz, D. Drug Resistance in Cancer: Principles of Emergence and Prevention Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 9714-9719
78. Hrkach, J.; Von Hoff, D.; Ali, M. M.; Andrianova, E.; Auer, J.; Campbell, T.; De Witt, D.; Figa, M.; Figueiredo, M.; Horhota, A. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile Sci. Transl. Med. 2012, 4, 128ra39
79. Sun, W.; Jiang, T.; Lu, Y.; Reiff, M.; Mo, R.; Gu, Z. Cocoon-like Self-Degradable DNA-Nanoclew for Anticancer Drug Delivery J. Am. Chem. Soc. 2014, 136, 14722-14725
80. Lu, Y.; Mo, R.; Tai, W.; Sun, W.; Pacardo, D. B.; Qian, C.; Shen, Q.; Ligler, F. S.; Gu, Z. Self-Folded Redox/Acid Dual-Responsive Nanocarriers for Anticancer Drug Delivery Chem. Commun. 2014, 50, 15105-15108
81. Lehmann, B. D.; Bauer, J. A.; Chen, X.; Sanders, M. E.; Chakravarthy, A. B.; Shyr, Y.; Pietenpol, J. A. Identification of Human Triple-Negative Breast Cancer Subtypes and Preclinical Models for Selection of Targeted Therapies J. Clin. Invest. 2011, 121, 2750-2767
82. Yamori, T. Panel of Human Cancer Cell Lines Provides Valuable Database for Drug Discovery and Bioinformatics Cancer Chemother. Pharmacol. 2003, 52, 74-79
83. Iorio, M. V.; Ferracin, M.; Liu, C.-G.; Veronese, A.; Spizzo, R.; Sabbioni, S.; Magri, E.; Pedriali, M.; Fabbri, M.; Campiglio, M. MicroRNA Gene Expression Deregulation in Human Breast Cancer Cancer Res. 2005, 65, 7065-7070